Dr. Wei Wang, MD

Dr. Wang practices at Bay Area Neurocare, Inc in San Jose, California.

Dr. Wang's NPI, 1396704482, was assigned on March 20, 2006. Dr. Wang graduated from Anhui Medical University in 1985. Dr. Wang holds California license A91418.

Dr. Wang's primary practice is Bay Area Neurocare, Inc, at 2504 Samaritan Dr, San Jose, CA 95124 in Santa Clara County. The practice phone is (408) 216-8763.

Dr. Wang's primary practice is Bay Area Neurocare, Inc in San Jose, California. Dr. Wang is also affiliated with Good Samaritan Hospital. Dmand AI also links Dr. Wang to 3 more hospitals and 1 physician office, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Wang practices, 5 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Wang's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Wang is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Wang's licenses on file in 4 states: California, Indiana, Wisconsin and Pennsylvania.

Dmand AI lists acute mini-stroke (TIA), alzheimer's disease, carpal tunnel syndrome, cerebrovascular disease, epilepsy, essential tremor, fibromyalgia and chronic pain and hypersomnia among the conditions Dr. Wang treats.

CMS data shows 2,443 Medicare services from Dr. Wang across 14 procedure codes in 2024, for 437 Medicare patients. Medicare paid $270,162 for them.

CMS counts 437 Medicare patients who saw Dr. Wang in 2024. The largest group is 75 to 84, with 172 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 33% are also on Medicaid. Their average risk score is 1.52, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Wang's median patient age at 69, with 46% women.

In 2024, Dr. Wang wrote 820 Medicare Part D claims for 150 patients. 96% of them were for generic drugs. CMS names the drug for 764 of them, across 22 drugs with 11 or more claims each, at $59,729 in total drug cost. In 2023, CMS named 678 claims across 21 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Wang for performance year 2024, reported individually. Dr. Wang accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

Dmand AI links 479 papers to Dr. Wang, published from 2001 to 2024. 2016 was the busiest year, with 37. The most frequent topics are Cell Line, Tumor, China and Cell Proliferation. Dr. Wang has published most often in Sci Rep. Dr. Wang's most frequent co-authors are Elizabeth Christine Tyler-Kabara, MD, PhD, Clark A. Rosen, MD and Sherwin Shiu-Cheung Chan, MD.

Dmand AI links Dr. Wang to 4 clinical trials, 3 of them phase 3 studies. Conditions studied include Breast Neoplasms, Multiple Endocrine Neoplasia Type 1 and Breast Diseases. Novartis Pharmaceuticals sponsors the most, 4.

CMS Open Payments shows 5 general payments to Dr. Wang from 4 drug and device companies from 2017 to 2024. Food and beverage make up the largest share, 100% of the total. Mallinckrodt Hospital Products Inc. paid the most, $140.

Dr. Wang graduated from Anhui Medical University in 1985. Dr. Wang is a member of AAN, AASM and AANEM.

Dr. Wang is in network with 16 carriers, including Aetna, Blue Cross Blue Shield of Michigan and United Healthcare. PPO plans come from the most carriers, 10. Check the plan with the practice before a visit.